MolecularMD

About:

MolecularMD provides molecular diagnostics products and services to support clinical development and commercialization of cancer therapies.

Website: http://www.molecularmd.com

Top Investors: Ballast Point Ventures, Nextech Invest

Description:

MolecularMD Corporation develops and commercializes specialty molecular diagnostics for oncology applications. Its tests are designed to allow appropriate selection, monitoring and management of patients treated with molecularly targeted cancer therapies. MolecularMD’s assays incorporate both gold-standard and innovative technologies to provide highly sensitive, standardized, reliable results that support clinical development, regulatory approval, and commercialization of novel anticancer agents. A private company based in Portland, Oregon, MolecularMD was founded by Brian Druker, director of the Knight Cancer Center at Oregon Health & Science University, and Sheridan G. Snyder, entrepreneur and founder of Genzyme Corporation and Upstate Biotechnology.

Total Funding Amount:

$14M

Estimated Revenue Range:

$10M to $50M

Headquarters Location:

Portland, Oregon, United States

Founded Date:

2005-01-01

Contact Email:

Info(AT)MolecularMD.com

Founders:

Brian Druker, Chad Galderisi, Sheridan Snyder

Number of Employees:

101-250

Last Funding Date:

2017-02-13

IPO Status:

Private

Industries:

© 2025 bioDAO.ai